Cargando…
Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
OBJECTIVE: In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were co...
Autores principales: | Kitajima, Kazuhiro, Watabe, Tadashi, Nakajo, Masatoyo, Ishibashi, Mana, Daisaki, Hiromitsu, Soeda, Fumihiko, Tanemura, Atsushi, Kanekura, Takuro, Yamazaki, Naoya, Ito, Kimiteru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732811/ https://www.ncbi.nlm.nih.gov/pubmed/34287739 http://dx.doi.org/10.1007/s11604-021-01174-w |
Ejemplares similares
-
A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article
por: Nakajo, Masatoyo, et al.
Publicado: (2021) -
Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022) -
Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016) -
Usefulness of semi-automatic harmonization strategy of standardized uptake values for multicenter PET studies
por: Daisaki, Hiromitsu, et al.
Publicado: (2021) -
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)